Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
8.12
USD
|
+3.57%
|
|
+10.48%
|
-17.65%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,895
|
1,461
|
2,136
|
1,932
|
-
|
-
|
Enterprise Value (EV)
1 |
2,379
|
918.1
|
1,745
|
1,610
|
1,654
|
1,660
|
P/E ratio
|
-11.5
x
|
-5.67
x
|
-6.24
x
|
-4.78
x
|
-4.33
x
|
-6.58
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
284
x
|
36.7
x
|
47.9
x
|
35.8
x
|
31.9
x
|
12.8
x
|
EV / Revenue
|
234
x
|
23
x
|
39.2
x
|
29.9
x
|
27.3
x
|
11
x
|
EV / EBITDA
|
-13.6
x
|
-3.92
x
|
-5.36
x
|
-3.94
x
|
-3.27
x
|
-3.33
x
|
EV / FCF
|
-12
x
|
-7.61
x
|
-5.82
x
|
-4.27
x
|
-3.99
x
|
-6.13
x
|
FCF Yield
|
-8.34%
|
-13.1%
|
-17.2%
|
-23.4%
|
-25%
|
-16.3%
|
Price to Book
|
5.37
x
|
2.79
x
|
4.97
x
|
5.79
x
|
8.98
x
|
12.7
x
|
Nbr of stocks (in thousands)
|
168,993
|
189,556
|
216,623
|
237,983
|
-
|
-
|
Reference price
2 |
17.13
|
7.710
|
9.860
|
8.120
|
8.120
|
8.120
|
Announcement Date
|
3/23/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3.962
|
10.18
|
39.84
|
44.58
|
53.92
|
60.67
|
151.4
|
EBITDA
1 |
-
|
-174.4
|
-234
|
-325.7
|
-408.5
|
-506.1
|
-499
|
EBIT
1 |
-
|
-182.8
|
-245.7
|
-350.1
|
-425.2
|
-506.3
|
-467.2
|
Operating Margin
|
-
|
-1,795.79%
|
-616.74%
|
-785.33%
|
-788.59%
|
-834.61%
|
-308.5%
|
Earnings before Tax (EBT)
1 |
-
|
-186.5
|
-239.5
|
-332.1
|
-438
|
-533
|
-398
|
Net income
1 |
-87.01
|
-186.5
|
-239.5
|
-328.1
|
-410.5
|
-481.2
|
-398
|
Net margin
|
-2,196.01%
|
-1,832.18%
|
-601.05%
|
-735.99%
|
-761.41%
|
-793.21%
|
-262.8%
|
EPS
2 |
-5.990
|
-1.490
|
-1.360
|
-1.580
|
-1.699
|
-1.877
|
-1.234
|
Free Cash Flow
1 |
-
|
-198.4
|
-120.6
|
-299.7
|
-377
|
-414
|
-271
|
FCF margin
|
-
|
-1,949.42%
|
-302.65%
|
-672.43%
|
-699.2%
|
-682.41%
|
-178.95%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/21
|
3/23/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
2.534
|
2.533
|
5.333
|
7.674
|
13.16
|
13.68
|
12.13
|
11.02
|
10.53
|
10.89
|
13.07
|
13.58
|
14.17
|
14.35
|
13.5
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-59.58
|
-
|
-66.14
|
-76.17
|
-
|
-91.38
|
-91.3
|
-91.3
|
-89.8
|
-184.8
|
-201.4
|
EBIT
1 |
-46.4
|
-64.96
|
-55.98
|
-66.19
|
-62.57
|
-60.98
|
-69.86
|
-81.72
|
-99.55
|
-98.93
|
-100.1
|
-101.6
|
-103
|
-130.7
|
-154.8
|
Operating Margin
|
-1,831.18%
|
-2,564.55%
|
-1,049.71%
|
-862.54%
|
-475.48%
|
-445.91%
|
-575.78%
|
-741.72%
|
-945.12%
|
-908.36%
|
-765.83%
|
-747.86%
|
-726.77%
|
-910.8%
|
-1,146.3%
|
Earnings before Tax (EBT)
1 |
-47.43
|
-64.93
|
-
|
-65.56
|
-60.44
|
-57.49
|
-65.33
|
-76.73
|
-93.02
|
-94.62
|
-106
|
-106
|
-108
|
-117
|
-
|
Net income
1 |
-47.43
|
-64.93
|
-55.98
|
-65.56
|
-60.44
|
-57.49
|
-65.33
|
-76.73
|
-93.02
|
-93
|
-98.92
|
-99.42
|
-99.68
|
-126
|
-154.8
|
Net margin
|
-1,871.67%
|
-2,563.48%
|
-1,049.67%
|
-854.31%
|
-459.31%
|
-420.39%
|
-538.38%
|
-696.43%
|
-883.1%
|
-853.88%
|
-757.08%
|
-731.96%
|
-703.59%
|
-878.4%
|
-1,146.3%
|
EPS
2 |
-0.2800
|
-0.3800
|
-0.3300
|
-0.3800
|
-0.3500
|
-0.3000
|
-0.3400
|
-0.3800
|
-0.4300
|
-0.4200
|
-0.4160
|
-0.4133
|
-0.4085
|
-0.4836
|
-0.6750
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/23/22
|
5/10/22
|
8/9/22
|
11/8/22
|
2/27/23
|
5/8/23
|
8/8/23
|
11/9/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
516
|
543
|
390
|
322
|
279
|
272
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-198
|
-121
|
-300
|
-377
|
-414
|
-271
|
ROE (net income / shareholders' equity)
|
-
|
-111%
|
-46.6%
|
-69.1%
|
-98.9%
|
-157%
|
-205%
|
ROA (Net income/ Total Assets)
|
-
|
-41%
|
-36.5%
|
-48.4%
|
-75.2%
|
-114%
|
-98.3%
|
Assets
1 |
-
|
454.5
|
655.8
|
677.5
|
546.2
|
421.4
|
404.7
|
Book Value Per Share
2 |
-
|
3.190
|
2.770
|
1.980
|
1.400
|
0.9000
|
0.6400
|
Cash Flow per Share
2 |
-
|
-1.270
|
-0.4800
|
-1.380
|
-0.9900
|
-0.5800
|
-
|
Capex
1 |
-
|
39.8
|
37.1
|
12
|
13
|
14
|
16
|
Capex / Sales
|
-
|
391.02%
|
93.01%
|
26.82%
|
24.11%
|
23.08%
|
10.57%
|
Announcement Date
|
3/3/21
|
3/23/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
8.12
USD Average target price
13
USD Spread / Average Target +60.10% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.65% | 1.93B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|